Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
PIK3CA protein
breast neoplasms
circulating tumour DNA
human
maximum tolerated dose
phosphoinositide-3 kinase (PI3K)
trastuzumab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Mar 2021
11 Mar 2021
Historique:
received:
30
01
2021
revised:
03
03
2021
accepted:
07
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Activation of the phosphoinositide-3 kinase (PI3K) pathway is a resistance mechanism to anti-human epidermal growth factor receptor 2 (HER2) therapy. This phase Ib trial was conducted to determine the maximum tolerated dose (MTD) of copanlisib, an intravenous (IV) pan-class I PI3K inhibitor, combined with trastuzumab. Patients with advanced HER2-positive breast cancer and disease progression following at least one prior line of HER2 therapy in the metastatic setting were treated with copanlisib (45 or 60 mg) IV on days 1, 8 and 15 of a 28-day cycle with a fixed dose of trastuzumab 2 mg/kg weekly. Twelve patients were enrolled. The MTD was determined as copanlisib 60 mg plus trastuzumab 2 mg/kg weekly. The most common adverse events of any grade occurring in more than two patients were hyperglycaemia (58%), fatigue (58%), nausea (58%) and hypertension (50%). Stable disease was confirmed at 16 weeks in six participants (50%). Copanlisib and trastuzumab can be safely administered with fair overall tolerability. Preliminary evidence of tumour stability was observed in patients with heavily pre-treated, metastatic HER2 positive breast cancer. Several potential biomarkers were identified for further study in the current phase 2 clinical trial. NCT: 02705859.
Sections du résumé
BACKGROUND
BACKGROUND
Activation of the phosphoinositide-3 kinase (PI3K) pathway is a resistance mechanism to anti-human epidermal growth factor receptor 2 (HER2) therapy. This phase Ib trial was conducted to determine the maximum tolerated dose (MTD) of copanlisib, an intravenous (IV) pan-class I PI3K inhibitor, combined with trastuzumab.
METHODS
METHODS
Patients with advanced HER2-positive breast cancer and disease progression following at least one prior line of HER2 therapy in the metastatic setting were treated with copanlisib (45 or 60 mg) IV on days 1, 8 and 15 of a 28-day cycle with a fixed dose of trastuzumab 2 mg/kg weekly.
RESULTS
RESULTS
Twelve patients were enrolled. The MTD was determined as copanlisib 60 mg plus trastuzumab 2 mg/kg weekly. The most common adverse events of any grade occurring in more than two patients were hyperglycaemia (58%), fatigue (58%), nausea (58%) and hypertension (50%). Stable disease was confirmed at 16 weeks in six participants (50%).
CONCLUSION
CONCLUSIONS
Copanlisib and trastuzumab can be safely administered with fair overall tolerability. Preliminary evidence of tumour stability was observed in patients with heavily pre-treated, metastatic HER2 positive breast cancer. Several potential biomarkers were identified for further study in the current phase 2 clinical trial. NCT: 02705859.
Identifiants
pubmed: 33799597
pii: cancers13061225
doi: 10.3390/cancers13061225
pmc: PMC7999809
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Health Research Board
ID : ILP-POR-2019-006
Pays : Ireland
Organisme : Irish Cancer Society
ID : CCRC13GAL
Organisme : North East Cancer Research and Education Trust
ID : N/A
Organisme : Fox and Kerins Families
ID : N/A
Références
Nature. 2018 Aug;560(7719):499-503
pubmed: 30051890
J Clin Oncol. 2017 Jan 10;35(2):141-148
pubmed: 28056202
Cancer Cell. 2009 May 5;15(5):429-40
pubmed: 19411071
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Cell. 1998 Aug 7;94(3):363-74
pubmed: 9708738
Ann Oncol. 2016 Oct;27(10):1928-40
pubmed: 27672108
Bioinformatics. 2010 Aug 15;26(16):2069-70
pubmed: 20562413
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Clin Cancer Res. 2012 Dec 15;18(24):6784-91
pubmed: 23092874
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Breast Cancer Res Treat. 2015 Jan;149(2):373-83
pubmed: 25528022
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Anticancer Drugs. 2012 Sep;23(8):765-76
pubmed: 22824822
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Mol Cancer Ther. 2013 Nov;12(11):2319-30
pubmed: 24170767
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
Cancer Res. 2002 Jul 15;62(14):4132-41
pubmed: 12124352
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
pubmed: 16341064
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Cancer Res. 2008 Aug 1;68(15):6084-91
pubmed: 18676830
J Breast Cancer. 2016 Mar;19(1):61-7
pubmed: 27066097
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Ann Oncol. 2017 Sep 1;28(9):2169-2178
pubmed: 28633365
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943